| Oct 30 |
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Oct 29 |
Amarin Q3 2024 Earnings Preview
|
| Oct 9 |
Amarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
|
| Oct 1 |
Amarin Announces Two Upcoming Investor Events
|
| Sep 18 |
Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation
|
| Sep 9 |
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Eur...
|
| Aug 22 |
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
|
| Aug 8 |
Exploring 3 Undervalued Small Caps In United States With Insider Action
|
| Aug 1 |
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
|
| Jul 31 |
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
|
